Thoetchai Bee Peeraphatdit1, Patrick S Kamath1, Victor M Karpyak2, Brian Davis3, Vivek Desai4, Suthat Liangpunsakul5, Arun Sanyal3, Naga Chalasani6, Vijay H Shah1, Douglas A Simonetto7. 1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota. 2. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minnesota. 3. Division of Gastroenterology and Hepatology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia. 4. Department of Family Medicine, Institute for Family Health, New York, New York. 5. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Roudebush Veterans Administration Medical Center, Indianapolis, Indiana. 6. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 7. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota. Electronic address: simonetto.douglas@mayo.edu.
Abstract
BACKGROUND & AIMS: Patients admitted to the hospital for alcoholic hepatitis (AH) are at increased risk of readmission and death. We aimed to identify factors associated with readmission, alcohol relapse, and mortality. METHODS: We performed a retrospective analysis of consecutive patients admitted with AH to a tertiary care hospital from 1999 through 2016 (test cohort, n = 135). We validated our findings in a prospective analysis of patients in a multi-center AH research consortium from 2013 through 2017 (validation cohort, n = 159). Alcohol relapse was defined as any amount of alcohol consumption within 30 days after hospital discharge. Early alcohol rehabilitation was defined as residential or outpatient addiction treatment or mutual support group participation within 30 days after hospital discharge. RESULTS: Thirty-day readmission rates were 30% in both cohorts. Alcohol relapse rates were 37% in the test and 34% in the validation cohort. Following hospital discharge, 27 patients (20%) in the test cohort and 19 patients (16%) in the validation cohort attended early alcohol rehabilitation. There were 53 deaths (39%) in a median follow-up time of 2.8 years and 42 deaths (26%) in a median follow-up time of 1.3 years, respectively. In the test cohort, early alcohol rehabilitation reduced odds for 30-day readmission (adjusted odds ratios [AOR] 0.16; 95% CI, 0.04-0.65; P = .01), 30-day alcohol relapse (AOR, 0.11; 95% CI, 0.02-0.53; P < .001), and death (adjusted hazard ratio [AHR], 0.20; 95% CI, 0.05-0.56; P = .001). In the validation cohort early alcohol rehabilitation reduced odds for 30-day readmission (AOR, 0.30; 95% CI, 0.09-0.98; P = .04), 30-day alcohol relapse (AOR 0.09; 95% CI, 0.01-0.73; P = .02), and death (AHR, 0.20; 95% CI, 0.01-0.94; P = .04). A model combining alcohol rehabilitation and bilirubin identified patients with readmission to the hospital within 30 days with an area under the receiver operating characteristic curve of 0.73. CONCLUSIONS: In an analysis from two cohorts of patients admitted with AH, early alcohol rehabilitation can reduce risk of hospital readmission, alcohol relapse, and death and should be considered as a quality indicator in AH hospitalization treatment.
BACKGROUND & AIMS:Patients admitted to the hospital for alcoholic hepatitis (AH) are at increased risk of readmission and death. We aimed to identify factors associated with readmission, alcohol relapse, and mortality. METHODS: We performed a retrospective analysis of consecutive patients admitted with AH to a tertiary care hospital from 1999 through 2016 (test cohort, n = 135). We validated our findings in a prospective analysis of patients in a multi-center AH research consortium from 2013 through 2017 (validation cohort, n = 159). Alcohol relapse was defined as any amount of alcohol consumption within 30 days after hospital discharge. Early alcohol rehabilitation was defined as residential or outpatient addiction treatment or mutual support group participation within 30 days after hospital discharge. RESULTS: Thirty-day readmission rates were 30% in both cohorts. Alcohol relapse rates were 37% in the test and 34% in the validation cohort. Following hospital discharge, 27 patients (20%) in the test cohort and 19 patients (16%) in the validation cohort attended early alcohol rehabilitation. There were 53 deaths (39%) in a median follow-up time of 2.8 years and 42 deaths (26%) in a median follow-up time of 1.3 years, respectively. In the test cohort, early alcohol rehabilitation reduced odds for 30-day readmission (adjusted odds ratios [AOR] 0.16; 95% CI, 0.04-0.65; P = .01), 30-day alcohol relapse (AOR, 0.11; 95% CI, 0.02-0.53; P < .001), and death (adjusted hazard ratio [AHR], 0.20; 95% CI, 0.05-0.56; P = .001). In the validation cohort early alcohol rehabilitation reduced odds for 30-day readmission (AOR, 0.30; 95% CI, 0.09-0.98; P = .04), 30-day alcohol relapse (AOR 0.09; 95% CI, 0.01-0.73; P = .02), and death (AHR, 0.20; 95% CI, 0.01-0.94; P = .04). A model combining alcohol rehabilitation and bilirubin identified patients with readmission to the hospital within 30 days with an area under the receiver operating characteristic curve of 0.73. CONCLUSIONS: In an analysis from two cohorts of patients admitted with AH, early alcohol rehabilitation can reduce risk of hospital readmission, alcohol relapse, and death and should be considered as a quality indicator in AH hospitalization treatment.
Authors: Juan P Arab; Tejasav S Sehrawat; Douglas A Simonetto; Vikas K Verma; Dechun Feng; Tom Tang; Kevin Dreyer; Xiaoqiang Yan; William L Daley; Arun Sanyal; Naga Chalasani; Svetlana Radaeva; Liu Yang; Hugo Vargas; Mauricio Ibacache; Bin Gao; Gregory J Gores; Harmeet Malhi; Patrick S Kamath; Vijay H Shah Journal: Hepatology Date: 2020-04-27 Impact factor: 17.425
Authors: Lindsay Yoder; Andrea Mladenovic; Francis Pike; Raj Vuppalanchi; Haleigh Hanson; Laura Corbito; Archita P Desai; Naga Chalasani; Eric S Orman Journal: Am J Med Date: 2021-10-14 Impact factor: 4.965
Authors: Ashwani K Singal; Andrea DiMartini; Lorenzo Leggio; Juan P Arab; Yong-Fang Kuo; Vijay H Shah Journal: Alcohol Alcohol Date: 2022-09-10 Impact factor: 3.913
Authors: Ashwani K Singal; Paul Kwo; Allison Kwong; Suthat Liangpunsakul; Alexandre Louvet; Pranoti Mandrekar; Craig McClain; Jessica Mellinger; Gyongyi Szabo; Norah Terrault; Mark Thursz; Gerald S Winder; W Ray Kim; Vijay H Shah Journal: Hepatology Date: 2021-11-27 Impact factor: 17.298
Authors: Tejasav S Sehrawat; Juan P Arab; Mengfei Liu; Pouya Amrollahi; Meihua Wan; Jia Fan; Yasuhiko Nakao; Elisa Pose; Amaia Navarro-Corcuera; Debanjali Dasgupta; Chieh-Yu Liao; Li He; Amy S Mauer; Emma Avitabile; Meritxell Ventura-Cots; Ramon A Bataller; Arun J Sanyal; Naga P Chalasani; Julie K Heimbach; Kymberly D Watt; Gregory J Gores; Pere Gines; Patrick S Kamath; Douglas A Simonetto; Tony Y Hu; Vijay H Shah; Harmeet Malhi Journal: Hepatology Date: 2020-10-30 Impact factor: 17.425